CATO’s New Cosmetic Active Ingredient Series

As skincare formulation becomes more sophisticated, functional active ingredients are now central to product innovation and differentiation. For too long, the high-end cosmetic actives market has been dominated by a handful of global suppliers—resulting in high costs, long lead times, and limited sourcing flexibility for brands worldwide. To meet the growing demand for reliable, high-performance ingredients, CATO introduces its new Cosmetic Active Ingredient Series, featuring a diverse portfolio covering:

Notice on Packaging Change of CATO Products

Announcement on the Packaging Upgrade of CATO Reference Standards

REACH Annex XVII Adds New Restrictions on DMAC and NEP

On June 3, 2025, the European Union officially published Commission Regulation (EU) 2025/1090 in its Official Journal, introducing significant amendments to REACH Regulation Annex XVII by adding Articles 80 and 81. Two important industrial solvents—N,N-dimethylacetamide (DMAC) and 1-ethylpyrrolidin-2-one (NEP)—have been formally included in the restricted substances list.

CATO's Azithromycin-D5: Powering Precision Analytics

Azithromycin-D5 is synthesized by selectively replacing five specific hydrogen atoms in the azithromycin molecular structure with deuterium. It retains identical chemical properties while exhibiting distinct mass spectrometric characteristics.

Recommended Major Nitrosamine Impurities : N-Nitroso Finerenone

In recent years, drug safety issues have received significant attention. Among these, nitrosamine impurities have become a "Sword of Damocles" hanging over pharmaceutical companies. On March 28, 2025, the FDA updated its "Nitrosamine Impurities Acceptable Intake Limits" database. This update primarily added and adjusted acceptable intake limits for multiple nitrosamine impurities and expanded the substance categories determined by the prediction-based carcinogenic potency classification approach (CPCA), further strengthening drug safety regulations.

CATO Attend 75th PITTCON Conference and Exposition

From February 24-28, 2024, the 2024 Pittcon Analytical Chemistry and Spectroscopy Applications Conference and Exhibition will be held at the San Diego Convention Center.

Overcoming the Three-Disulfide-Bond Purification Barrier: Linaclotide Impurity Profiling and Deficiency Response Strategies

Overcoming the Three-Disulfide-Bond Purification Barrier: Li

Lidocaine Impurity Profile: Genotoxic Aniline Impurity and NDSRI Risk Under Control

Now Available | CATO Acyclovir EP Impurity R – Empowering Antiviral Drug Quality Control

To support quality research and registration submissions, CATO's in-house developed Impurity R reference standard features high purity and high stability, complete with comprehensive Certificate of Analysis (COA), making it widely applicable for process optimization, method development, registration dossier preparation, and various other application requirements.

FDA Adds 12 High-Risk Nitrosamine Impurities, Spotlighting Meglumine-Related NDSRIs

Recently, the U.S. FDA updated its Nitrosamine Impurities Acceptable Intake Limits database, adding 12 new high-risk nitrosamine impurities. Among them, meglumine-related nitrosamine drug substance-related impurities (NDSRIs) have emerged as a major pharmaceutical safety concern, involving more than ten commonly used drugs such as delafloxacin meglumine, iopamidol meglumine, and gadodiamide meglumine.